Coronavirus Outbreak Contributes to Delays in Sensorion’s Sudden Hearing Loss Phase II Clinical Trial
MONTPELLIER, FRANCE — Sensorion, a clinical-stage biotech company specializing in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has announced updated timelines for the ongoing Phase 2 study of SENS-401 to treat Sudden Sensorineural Hearing Loss (SSNHL). Patient recruitment rates from this trial now indicate the…
Read MoreGene Therapy Expert, Dr. Géraldine Honnet, Appointed as Sensorion’s New Chief Medical Officer
MONTPELLIER, FRANCE — Sensorion, a clinical-stage biotech company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, has announced the appointment of gene therapy expert Géraldine Honnet MD, as Chief Medical Officer. Géraldine Honnet is a medical doctor and joins from Généthon, where she…
Read MoreSensorion Receives $6.2M in Funding to Support SENS-401 Phase 2 Study in Sudden Sensorineural Hearing Loss
MONTPELLIER, FRANCE — French biotech firm Sensorion has announced that the French government has awarded the PATRIOT consortium a Structuring Research and Development Project for Competitiveness (“Projet de recherche et développement Structurant pour la Compétitivité” – PSPC) non-dilutive funding. The grant will be used to finance the development of SENS-401 in SSNHL, including work by Institut Pasteur to…
Read MoreSensorion Announces Disappointing Results From SENS-111 Phase 2b Trial in Acute Unilateral Vestibulopathy
MONTPELLIER, FRANCE — Biotech firm Sensorion has reported results from a Phase 2 proof-of-concept trial of SENS-111 for the treatment of acute unilateral vestibulopathy (AUV). SENS-111 was reported to be safe and well tolerated. However, it did not meet the primary endpoint of vertigo intensity, measured by the area under the curve of the vertigo…
Read MoreSensorion Announces Poster Presentation of New SENS-401 Preclinical Data at SFN 2019
MONTPELLIER, FRANCE — French biotech firm Sensorion, which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo, announced that it has contributed a poster presentation at the 2019 Annual Meeting of the Society for Neuroscience (SFN 2019) held in Chicago from the…
Read More
Sensorion Receives FDA Investigational New Drug Clearance for Arazasetron (SENS-401)
MONTPELLIER, FRANCE — French biotech firm Sensorion, which specializes in the development of novel therapies to restore, treat and prevent inner ear diseases such as hearing loss, tinnitus and vertigo, announced today that it has received the Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to proceed with SENS-401, based on…
Read More
Sensorion Announces Partnership Framework Agreement with Institut Pasteur on Gene Therapy Programs for Hearing Loss
MONTPELLIER, FRANCE — French biotech firm Sensorion has announced the signature of a research partnership framework agreement with Institut Pasteur (Paris) granting to Sensorion an option to obtain exclusive licenses to develop and market drug candidates in gene therapy coming from collaborative projects, for the restoration, treatment and prevention of hearing disorders. In accordance with…
Read MoreSensorion Enters Exclusive Negotiations with Pasteur Institute for Hearing Loss Gene Therapy Programs
MONTPELLIER, FRANCE — Biotech firm Sensorion announced that it has entered into a letter of intent with the Paris, France-based Pasteur Institute to exclusively negotiate a framework agreement to obtain the exclusive licenses to develop and commercialize gene therapy product candidates for restoration, treatment and prevention of hearing loss disorders. The Pasteur Institute Unit of…
Read MoreSensorion to Begin Patient Enrollment for Safety Study of Vertigo Drug, Seliforant
MONTPELLIER, FRANCE — Biotech firm Sensorion announced the initiation of patient enrollment in a Phase 2a study (SENS-111-202) to confirm the absence of certain side effects commonly experienced with meclizine (specifically, anticholinergic side effects like sedation and memory loss) during an evoked vestibular imbalance. SENS-111-202 is a randomized, double-blind, double-dummy, placebo-controlled, cross-over trial in patients designed…
Read More
Cochlear Ltd Announces Research Study Collaboration, and $1.9M Placement, with Sensorion
SYDNEY, AUSTRALIA — Hearing implant maker, Cochlear Ltd, announced a strategic collaboration with French biotech firm, Sensorion. The collaboration will examine therapeutic approaches using Sensorion’s investigative drug, SENS-401, in combination with cochlear implants. According to the press release, the preclinical studies will be initiated in 2018, with possible clinical trials beginining as early as 2019.…
Read More